Interpace Biosciences, Inc.

General ticker "IDXG" information:

  • Sector: Health Care
  • Industry: Health Care Providers & Services
  • Capitalization: $7.4M (TTM average)

Interpace Biosciences, Inc. follows the US Stock Market performance with the rate: 27.4%.

Estimated limits based on current volatility of 11.3%: low 0.77$, high 0.97$

Factors to consider:

  • Earnings expected soon, date: nan
  • Current price 66.4% below estimated low
  • Earnings for 12 months up through Q4 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [0.89$, 4.10$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.93$, 6.87$]

Financial Metrics affecting the IDXG estimates:

  • Positive: Operating cash flow per share per price, % of 83.21 > 12.73
  • Positive: 0.04 < Non-GAAP EPS, $ of 0.28
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Negative: Industry operating cash flow per share per price (median), % of 3.81 <= 6.49
  • Negative: Shareholder equity ratio, % of -473.63 <= 22.52
  • Positive: Return on assets ratio (scaled to [-100,100]) of 7.87 > 6.86
  • Negative: Operating profit margin, % of 6.97 <= 8.37
  • Positive: Inventory ratio change, % of -0.74 <= 0

Similar symbols

Short-term IDXG quotes

2025-03-142025-03-172025-03-182025-03-192025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-250.40.60.811.21.4
Price $

Long-term IDXG plot with estimates

1234567Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025−0.4−0.200.20.4
IDXGS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $33.12MM $31.84MM $40.21MM
Operating Expenses $39.45MM $35.45MM $37.41MM
Operating Income $-6.34MM $-3.62MM $2.80MM
Non-Operating Income $-1.41MM $-2.22MM $-1.68MM
Interest Expense $0.50MM $0.16MM $0.90MM
R&D Expense $1.49MM $0.70MM $0.64MM
Income(Loss) $-7.74MM $-5.84MM $1.13MM
Taxes $-0.70MM $0.03MM $0.02MM
Other Income(Loss) $-7.91MM $-16.09MM $-0.31MM
Profit(Loss)* $-14.75MM $-5.87MM $0.49MM
Stockholders Equity $-42.42MM $-63.07MM $-61.67MM
Inventory $1.79MM $1.22MM $1.23MM
Assets $38.43MM $15.98MM $13.02MM
Operating Cash Flow $-8.72MM $-7.69MM $3.79MM
Capital expenditure $0.35MM $0.32MM $0.47MM
Investing Cash Flow $-0.32MM $6.21MM $-0.09MM
Financing Cash Flow $8.98MM $3.00MM $-5.03MM
Earnings Per Share** $-3.57 $-1.38 $0.11

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.